Felgner Sebastian, Frahm Michael, Kocijancic Dino, Rohde Manfred, Eckweiler Denitsa, Bielecka Agata, Bueno Emilio, Cava Felipe, Abraham Wolf-Rainer, Curtiss Roy, Häussler Susanne, Erhardt Marc, Weiss Siegfried
Department of Molecular Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany
Department of Molecular Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
mBio. 2016 Sep 6;7(5):e01220-16. doi: 10.1128/mBio.01220-16.
Recombinant attenuated Salmonella enterica serovar Typhimurium strains are believed to act as powerful live vaccine carriers that are able to elicit protection against various pathogens. Auxotrophic mutations, such as a deletion of aroA, are commonly introduced into such bacteria for attenuation without incapacitating immunostimulation. In this study, we describe the surprising finding that deletion of aroA dramatically increased the virulence of attenuated Salmonella in mouse models. Mutant bacteria lacking aroA elicited increased levels of the proinflammatory cytokine tumor necrosis factor alpha (TNF-α) after systemic application. A detailed genetic and phenotypic characterization in combination with transcriptomic and metabolic profiling demonstrated that ΔaroA mutants display pleiotropic alterations in cellular physiology and lipid and amino acid metabolism, as well as increased sensitivity to penicillin, complement, and phagocytic uptake. In concert with other immunomodulating mutations, deletion of aroA affected flagellin phase variation and gene expression of the virulence-associated genes arnT and ansB Finally, ΔaroA strains displayed significantly improved tumor therapeutic activity. These results highlight the importance of a functional shikimate pathway to control homeostatic bacterial physiology. They further highlight the great potential of ΔaroA-attenuated Salmonella for the development of vaccines and cancer therapies with important implications for host-pathogen interactions and translational medicine.
Recombinant attenuated bacterial vector systems based on genetically engineered Salmonella have been developed as highly potent vaccines. Due to the pathogenic properties of Salmonella, efficient attenuation is required for clinical applications. Since the hallmark study by Hoiseth and Stocker in 1981 (S. K. Hoiseth and B. A. D. Stocker, Nature 291:238-239, 1981, http://dx.doi.org/10.1038/291238a0), the auxotrophic ΔaroA mutation has been generally considered safe and universally used to attenuate bacterial strains. Here, we are presenting the remarkable finding that a deletion of aroA leads to pronounced alterations of gene expression, metabolism, and cellular physiology, which resulted in increased immunogenicity, virulence, and adjuvant potential of Salmonella. These results suggest that the enhanced immunogenicity of aroA-deficient Salmonella strains might be advantageous for optimizing bacterial vaccine carriers and immunotherapy. Accordingly, we demonstrate a superior performance of ΔaroA Salmonella in bacterium-mediated tumor therapy. In addition, the present study highlights the importance of a functional shikimate pathway to sustain bacterial physiology and metabolism.
重组减毒鼠伤寒沙门氏菌菌株被认为是强大的活疫苗载体,能够引发针对多种病原体的保护作用。营养缺陷型突变,如aroA缺失,通常被引入此类细菌以实现减毒,同时又不丧失免疫刺激能力。在本研究中,我们描述了一个惊人的发现,即在小鼠模型中,aroA缺失显著增加了减毒沙门氏菌的毒力。缺乏aroA的突变细菌在全身应用后引发了促炎细胞因子肿瘤坏死因子α(TNF-α)水平的升高。结合转录组学和代谢谱分析的详细遗传和表型特征表明,ΔaroA突变体在细胞生理学、脂质和氨基酸代谢方面表现出多效性改变,并且对青霉素、补体和吞噬摄取的敏感性增加。与其他免疫调节突变协同作用,aroA缺失影响鞭毛蛋白相变以及毒力相关基因arnT和ansB的基因表达。最后,ΔaroA菌株显示出显著改善的肿瘤治疗活性。这些结果突出了功能性莽草酸途径对控制细菌内稳态生理的重要性。它们进一步突出了ΔaroA减毒沙门氏菌在疫苗和癌症治疗开发方面的巨大潜力,这对宿主 - 病原体相互作用和转化医学具有重要意义。
基于基因工程沙门氏菌的重组减毒细菌载体系统已被开发为高效疫苗。由于沙门氏菌的致病特性,临床应用需要有效的减毒方法。自1981年Hoiseth和Stocker的标志性研究(S.K. Hoiseth和B.A.D. Stocker,《自然》杂志291:238 - 239,1981,http://dx.doi.org/10.1038/291238a0)以来,营养缺陷型ΔaroA突变通常被认为是安全的,并被普遍用于减毒细菌菌株。在此,我们展示了一个显著的发现,即aroA缺失导致基因表达、代谢和细胞生理学的明显改变,这导致沙门氏菌的免疫原性、毒力和佐剂潜力增加。这些结果表明,aroA缺陷型沙门氏菌菌株增强的免疫原性可能有利于优化细菌疫苗载体和免疫疗法。因此,我们证明了ΔaroA沙门氏菌在细菌介导的肿瘤治疗中具有卓越的性能。此外,本研究突出了功能性莽草酸途径对维持细菌生理和代谢的重要性。